The Advisory Board Members
Alex Casson
University of Manchester - Professor
Alex Casson is Professor of Biomedical Engineering at the University of Manchester. He is a specialist in non-invasive bioelectronic interfaces: the design and application of wearable sensors, and skin-conformal flexible sensors, for human body monitoring and data analysis from highly artefact prone naturalistic situations. This work is highly multi-disciplinary, spanning ultra-low power sensing, signal processing and machine learning in power constrained rich environments, and real-time data analysis towards closed loop systems for remote monitoring and digital therapeutics. He has research experience in manufacturing, ultra-low power microelectronic circuit and system design at the discrete and fully custom microchip levels, sensor signal processing and machine learning for power and time constrained motion artefact rich environments, as well as using bespoke and off-the-shelf wearable devices in a wide range of environments.
Annette Bramley
N8 Research - Director & Chief Collaboration Officer
Since 2018 Annette has been the very driven and inspiring Director and ‘Chief Collaboration Officer’ of the N8 Research Partnership- the strongest university research alliance in the UK. As one of the UKs foremost experts in research culture she has become a regular, compelling and in demand speaker on the subject.
A graduate of Oxford University where she achieved a first-class degree and D.Phil in Materials Science, her particular niche is bringing people from different backgrounds to work together on research that has a tangible, genuine and long-lasting impact on the world. It’s fair to say N8’s successes in this arena are both as fascinating as they are many.
For over 20 years now she’s guided scientists and engineers of all disciplines at the Engineering and Physical Sciences Research Council (part of UK Research and Innovation) with great skill, inclusivity and creativity.
When not excelling in her profession Annette is also a gifted artist in the medium of embroidery and acrylic, and again to the highest accolade. She holds the Certificate in Technical Hand Embroidery from the Royal School of Needlework with Distinction and has exhibited countrywide.
As if all that isn’t impressive enough – her current side hustle is studying for a Professional Diploma in Group Sound Therapy.
Ariel Dowling
Takeda - Senior Director & Head of Sensing and Measurement Group
Ariel V. Dowling, PhD is a Senior Director and Head of the Sensing and Measurement group within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the assessment, validation, and deployment of digital devices and endpoints across the organization. Her group advises clinical teams on the selection of digital devices and endpoints, conducts due diligence on vendors and validation studies on devices, develops digital sensor implementation protocols and risk mitigation strategies, and assists with data analysis plans for device data. She was previously a Senior Clinical Data Scientist at Biogen Inc where she managed the wearable sensors deployed in clinical trials for Parkinson’s Disease. Prior to Biogen, Ariel was the algorithm team lead at MC10 Inc and worked at BioSensics LLC. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and an AB and BE in Mechanical Engineering from Dartmouth College. She currently serves on the Strategic Advisory Board of the Digital Medicine (DiMe) Society and Luca Healthcare.
David Dexter
Parkinson’s UK - Director of Research
Professor Dexter joined Parkinson’s UK on the 1st of March 2017 and became Direct of Research on the 1st of April 2023. David has 37 years research experience in Parkinson’s, 24 years of which was spent at Imperial College London where he was Professor of Neuropharmacology and Deputy Head of The Division of Brain Sciences. His research team made significant contributions into understanding the molecular mechanisms that cause Parkinson’s and in the development of novel therapeutics and founded the Parkinson’s UK Brain Bank in 2002. At Parkinson’s UK he manages the charities grants funding programmes, external research communications and involvement of people affected by Parkinson’s in research. David also manages Parkinson’s UK’s strategic partnerships such as the Critical Path for Parkinson’s etc. and is the biology lead in the Parkinson’s UK Virtual Biotech programme.
Dympna O’Sullivan
Digital Futures Research Hub – Academic Lead
Dympna O’Sullivan is the Academic Lead for Digital Futures Research Hub at TU Dublin. Prior to joining TU Dublin, she worked as a lecturer in Computer Science at Aston University in Birmingham and as a Senior Lecturer in Health Informatics at City, University of London. She completed her post-doctoral work with the Mobile Emergency Triage research group at the University of Ottawa. She holds a BSc and PhD in Computer Science from University College Dublin. Her research is in Health Informatics and in Computing Ethics.
In Health Informatics, her research interests are in the design, development and evaluation of Decision Support Systems to support clinician and patient decision making. This work involves research across many aspects of the domain including electronic and personal health records, machine learning and intelligent algorithms, explainable AI, sensors and smart home technologies, accessible user interfaces and theories of health behaviour change.
Her research in Computer Ethics focuses on the societal impacts of emerging technologies, which includes artificial intelligence, algorithmic decision-making and the associated privacy, fairness, transparency, and bias implications of AI. She develops methodologies for Explainable AI which aim to enhance the intelligibility of AI systems for end users. This research is underpinned by governance and legislation to ensure Trustworthy AI.
Elin Haf Davies
Aparito (a wholly owned subsidiary of Elli Lilly & Company) - Founder, Chief Scientific Officer & Executive Director
Elin Haf Davies career began as a Children’s Nurse and from there she spent time clinically, academically, and as a regulator, obtaining a BSc, MSc, and PhD along the way. Her combined experiences led her to establish Aparito in 2014, which aims to digitise clinical trials and accelerate drug development for life-limiting diseases. Aparito is a wholly owned subsidiary of Eli Lilly and Company.
Her approach is centred around the patient experience and intent to make clinical trials more accessible to everyone. Her mission for Aparito is to meet the needs of patients, physicians, regulators, and reimbursement agencies, and she remains devoted to the development of more meaningful outcome measures for patients engaged in clinical trials.
She enjoys the challenge of combining her professional career with extreme adventures which she finds brings both personal development and a different perspective to both.
Helen Matthews
Cure Parkinson’s - CEO
Helen has been a driving force behind the charity since it was formed over 17 years ago and has been instrumental in progressing some of the most promising and valuable research into finding a cure. Helen is well-known and highly engaged with the Parkinson’s community and brings a wealth of experience and knowledge to the helm.
Hubert Shum
Durham University – Professor and Director of Research
Hubert is a Professor of Visual Computing and the Director of Research of the Department of Computer Science at Durham University, specialising in modelling spatio–temporal information with responsible AI. He has authored over 180 research publications in the fields of Computer Vision, Computer Graphics, Machine Learning and Biomedical Engineering. He is a Co-Founder and the Co-Director of Durham University Space Research Centre. He has led research projects as the Principal Investigator awarded by EPSRC, the Ministry of Defence, the Royal Society and Innovate UK. He has also been a Co-Investigator in NortHFutures, a £4.17 mil EPSRC project to establish a new digital health hub in North East England. To engage academic and industrial networks, he has chaired international conferences such as Pacific Graphics, BMVC, ACM SIGGRAPH/Eurographics SCA and ACM SIGGRAPH MIG.
Jeremy Edgerton
Biogen - Director
Jeremy is a Medical Director in Movement Disorders Clinical Development at Biogen, based in Cambridge, Massachusetts. He has been involved in neuroscience research since 1994 when he cloned part of a novel splice variant of a calcium channel gene as an undergraduate. His grad and postdoctoral research used electrophysiological and computational approaches to investigate neuronal excitability and synaptic communication in cerebellar and basal ganglia circuits. He has worked in drug development since 2011, first in early discovery research at Pfizer Neuroscience, then moving into clinical stage research at Biogen in 2018 with a focus on digital measurement approaches for Parkinson’s disease and other movement disorders. He has designed and led the implementation of digital measurement plans for clinical trials in Parkinson’s disease, PSP, and cerebellar ataxias. He has also collaborated with industry and academic colleagues across the world to advance neuroscience drug development approaches through pre-competitive initiatives including 3DT (Digital Drug Development Tools) and PPMI (Parkinson’s Progression Markers Initiative).
Martijn Muller
Critical Path Institute – Senior Scientific Director
Martijn Muller, PhD, is a Senior Scientific Director for the Critical Path for Parkinson Consortium. Prior to joining C-Path, Martijn was Research Associate Professor of Radiology and Co-Director of the Clinical and Neuroimaging Resource Cores of the Udall Center of Excellence for Parkinson’s disease Research at the University of Michigan. Dr. Muller has a diverse research background with an established publication record in neuropsychology, biomechanics, and neuroimaging. He performed his PhD research at the University of Pittsburgh and was a researcher at the University of Michigan for nearly 15 years. Most of Dr. Muller’s research focused on in vivo neuroimaging correlates (particularly PET) of cognitive and mobility problems in Parkinson’s disease. Dr. Muller is particularly interested in how to incorporate wearable technology in a meaningful patient-oriented manner in Parkinson’s disease clinical trials.
Tim McCarthy - Chair
Pfizer - VP & Head
Tim McCarthy is VP & Head of Biomeasures, Endpoints and Study Technologies in Translational Clinical Sciences at Pfizer. His team works across the organization to develop biomarker plans and deliver key data to support the transition of assets across steps of the discovery and development process. The team has deep technical and operational knowledge and covers all biomarker and diagnostic technologies (circulating, imaging and digital). The team is enabled through key resources, such as the Clinical Biospecimens, Clinical Biomarker and Pfizer Innovation Research (PfIRe) Laboratories.
Tim has a background in Positron Emission Tomography, which he obtained during his time as a faculty member in Radiology at Washington University School of Medicine in St Louis. In 2001 Tim joined Pfizer to pursue his interests in applying translational imaging as a biomarker in drug development. During his time at Pfizer, his interests and responsibilities have expanded to cover digital health technologies, circulating biomarkers and the development of novel clinical endpoints across the organization. He is based in Cambridge, Massachusetts. Tim received his B.Sc. (Hons) and Ph.D. in Organic Chemistry from the University of Liverpool, UK and has an MBA from Washington University in St Louis. He served as the President of the Academy of Molecular Imaging (now World Molecular Imaging Society) between 2008 and 2011.
Trish Mensah
Bristol Older People’s Forum – Deputy Chair
Trish Mensah has been a trustee of Bristol Older People’s Forum in 2018 and is currently Deputy Chair which in turn involves sitting on several other committees – scrutiny in the Council as well as Housing and Toilet Committees with other local groups. Trish is also the membership secretary of GAS NPC (Gloucestershire, Avon and Somerset National Pensioners Convention) and an active member of Bristol Radical History Group and is currently writing pamphlets of older activists and their memories. Trish was on the board of Sphere and is also a member of BABCOM (Bladder and bowel confidence) and sits as a patient participant on a number of medical research projects (currently BABCOM and end of life care).
While at home raising four sons, Trish has been a foster carer, a school governor, as well as, on the board of BAND (Bristol Afterschool Neighbourhood Daycare) and started the local after school club (to enable her to return to university and change careers!) Trish was active in a number of campaigns such as the Anti-Apartheid movement and women’s rights. Trish was originally an Inpatient Services Manager in the NHS (managing services such as ward clerks, medical records, admissions, classification of diseases, waiting lists etc). She has a particular interest in Parkinson’s as my mother was 30 when first diagnosed so I have a good understanding of the disease and how it affects the person and their family.
While a senior social worker in Bristol Trish (initially in adult and hospital social worker and later with children in adoption and fostering) was also a trade union health and safety officer. Trish enjoys travel, playing board games, patchwork, reading and finding ancestors on Ancestry.
Walter Maetzler
University Hospital Kiel – Deputy Director
Walter Maetzler is a professor for neurogeriatrics and deputy director of the neurology department of the University Hospital in Kiel, Germany. His main clinical interest is on Parkinson’s disease and other age-related disorders, and geriatric conditions associated with functionally relevant movement and cognitive disabilities. He leads a research group focused on the analysis and validation of parameters that can be extracted from wearable sensor technology in supervised (“lab- or clinic-based”) and unsupervised (the home environment of the patients) assessments, and then be used to quantify movement, mobility, and human behaviour in these usual environments. He is contributing to new technology development, such as magnetoelectric sensors. He continues to be involved in multiple projects investigating the potential of mobile sensor technology to improve the understanding of disease progression and treatment response in age-related diseases.
Zuzana Hlásková
EPSRC - Portfolio Manager
Zuzana is a Portfolio Manager in Healthcare Technologies theme at EPSRC. She particularly looks after the ‘Digital Health’ and ‘Improving population health and prevention’ portfolios. She is also interested to hear more about opportunities and challenges within ‘Supporting knowledge and skills in health technologies’ space, which is one of the enablers outlined in the current EPSRC Health technologies strategy.